# PPP3CA

## Overview
The PPP3CA gene encodes the protein phosphatase 3 catalytic subunit alpha, which is a critical component of the calcineurin complex, a calcium/calmodulin-dependent serine/threonine phosphatase. This protein plays a pivotal role in calcium signaling pathways, influencing various cellular processes such as T-cell activation, synaptic plasticity, and muscle development. As a phosphatase, it is involved in the dephosphorylation of the nuclear factor of activated T-cells (NFAT), facilitating its nuclear translocation and subsequent gene regulation. Calcineurin, the protein complex that includes PPP3CA, is highly expressed in the brain and is essential for synaptic transmission and plasticity, linking it to memory and learning processes. Mutations in the PPP3CA gene have been associated with several neurodevelopmental disorders, including epilepsy and developmental delays, highlighting its clinical significance (Vaneynde2022The; Mizuguchi2018Lossoffunction; Roy2019Identifying).

## Structure
The PPP3CA gene encodes the catalytic subunit of calcineurin, a calcium/calmodulin-dependent serine/threonine phosphatase. The primary structure of the PPP3CA protein includes a catalytic domain and a calmodulin-binding domain, which are essential for its phosphatase activity (Mizuguchi2018Lossoffunction). The protein also contains several functional domains, including the calcineurin B-binding domain (CnBB), calmodulin-binding domain (CaMB), and an auto-inhibitory domain (AI) (Mizuguchi2018Lossoffunction).

The secondary structure of the PPP3CA protein is characterized by a significant proportion of α-helices and random coils, with α-helices comprising 43.25% of the structure (Wan2014Molecular). The tertiary structure involves a compact fold that facilitates substrate interaction, and the protein forms a heterodimer with regulatory subunits in its quaternary structure (Mizuguchi2018Lossoffunction).

Post-translational modifications of the PPP3CA protein include phosphorylation, which is crucial for its regulation and function (Wan2014Molecular). The protein's structure is further stabilized by metal-ion binding sites, which are essential for its catalytic activity (Mizuguchi2018Lossoffunction). These structural features are critical for the protein's role in calcium-dependent signal transduction.

## Function
The PPP3CA gene encodes the catalytic subunit of calcineurin, a calcium/calmodulin-dependent serine/threonine phosphatase, also known as PP2B. Calcineurin is a critical component in calcium signaling pathways, playing a significant role in various cellular processes. In healthy human cells, calcineurin is involved in the dephosphorylation of the nuclear factor of activated T-cells (NFAT), facilitating its translocation to the nucleus and subsequent regulation of gene expression. This process is crucial for T-cell activation and the adaptive immune response (Brautigan2018Protein; Roy2019Identifying).

Calcineurin is highly expressed in the brain, where it regulates synaptic plasticity and transmission by modulating ion channels and neurotransmitter receptors. It is involved in memory and synaptic plasticity, linking dopaminergic and glutamatergic signals, and is implicated in memory-associated disorders such as Alzheimer's disease (Vaneynde2022The; Chiocco2010Fine). Calcineurin also plays a role in embryonic neural induction and skeletal bone development, highlighting its importance in both neural and skeletal systems (Mizuguchi2018Lossoffunction).

In addition to its role in the nervous system, calcineurin is involved in muscle development and cardiac hypertrophy, underscoring its broad impact on organismal physiology through calcium signaling modulation (Roy2019Identifying).

## Clinical Significance
Mutations in the PPP3CA gene are associated with several neurodevelopmental disorders, primarily characterized by epilepsy and developmental delays. De novo mutations in PPP3CA have been linked to severe neurodevelopmental diseases with seizures, including early-onset refractory epilepsy and developmental and epileptic encephalopathies (Myers2017De). These mutations often result in loss-of-function, leading to conditions such as infantile or early childhood onset epileptic encephalopathy (IECEE1), which is marked by severe psychomotor delay, global developmental delay, and refractory seizures (Yang2020Clinical).

Gain-of-function mutations in PPP3CA, particularly in the autoinhibitory domain, are associated with a distinct set of clinical features, including arthrogryposis, cleft palate, craniosynostosis, and intellectual disability, with seizures being less common (Rydzanicz2018Novel; Yang2020Clinical). These mutations can lead to constitutive activation of the calcineurin protein, disrupting normal cellular signaling pathways and contributing to the pathogenesis of these disorders (Rydzanicz2018Novel).

The gene's mutations are also linked to specific syndromes such as West syndrome and Lennox-Gastaut syndrome, characterized by epileptic spasms and hypsarrhythmia (Mizuguchi2018Lossoffunction). The clinical significance of PPP3CA mutations underscores the gene's critical role in maintaining normal neurological function.

## Interactions
PPP3CA, also known as calcineurin A alpha, is involved in various protein interactions that are crucial for its function in cellular signaling pathways. It forms a multi-protein complex with CAMTA1 and NFATc4, which plays a significant role in mediating resistance to oxaliplatin in colorectal cancer. This complex is involved in the regulation of NFATc4 phosphorylation, with CAMTA1 acting as a tumor suppressor. The interaction between these proteins is essential for the proliferation, invasion, and chemoresistance of colorectal cancer cells (Pan2022CAMTA1–PPP3CA–NFATc4).

PPP3CA is also a client protein of HSP90 in multiple myeloma cells, where its degradation can be induced by histone deacetylase inhibitors like panobinostat. This interaction is crucial for the growth of multiple myeloma cells via NF-kB signaling (Imai2016Action).

In the context of neurological disorders, PPP3CA interacts with calmodulin in a calcium-dependent manner, which is vital for its role in dephosphorylating NFAT, facilitating its nuclear translocation (Mizuguchi2018Lossoffunction). These interactions highlight the diverse roles of PPP3CA in different cellular contexts and diseases.


## References


[1. (Vaneynde2022The) Pieter Vaneynde, Iris Verbinnen, and Veerle Janssens. The role of serine/threonine phosphatases in human development: evidence from congenital disorders. Frontiers in Cell and Developmental Biology, October 2022. URL: http://dx.doi.org/10.3389/fcell.2022.1030119, doi:10.3389/fcell.2022.1030119. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcell.2022.1030119)

[2. (Mizuguchi2018Lossoffunction) Takeshi Mizuguchi, Mitsuko Nakashima, Mitsuhiro Kato, Nobuhiko Okamoto, Hirokazu Kurahashi, Nina Ekhilevitch, Masaaki Shiina, Gen Nishimura, Takashi Shibata, Muneaki Matsuo, Tae Ikeda, Kazuhiro Ogata, Naomi Tsuchida, Satomi Mitsuhashi, Satoko Miyatake, Atsushi Takata, Noriko Miyake, Kenichiro Hata, Tadashi Kaname, Yoichi Matsubara, Hirotomo Saitsu, and Naomichi Matsumoto. Loss-of-function and gain-of-function mutations in ppp3ca cause two distinct disorders. Human Molecular Genetics, 27(8):1421–1433, February 2018. URL: http://dx.doi.org/10.1093/hmg/ddy052, doi:10.1093/hmg/ddy052. This article has 38 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddy052)

[3. (Brautigan2018Protein) David L. Brautigan and Shirish Shenolikar. Protein serine/threonine phosphatases: keys to unlocking regulators and substrates. Annual Review of Biochemistry, 87(1):921–964, June 2018. URL: http://dx.doi.org/10.1146/annurev-biochem-062917-012332, doi:10.1146/annurev-biochem-062917-012332. This article has 146 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1146/annurev-biochem-062917-012332)

[4. (Yang2020Clinical) Sai Yang, Xiang Shen, Qingyun Kang, Xiaojun Kuang, Zeshu Ning, Shulei Liu, Hongmei Liao, Zhenhua Cao, and Liming Yang. Clinical and genetic study on a chinese patient with infantile onset epileptic encephalopathy carrying a ppp3ca null variant: a case report. BMC Pediatrics, June 2020. URL: http://dx.doi.org/10.1186/s12887-020-02213-7, doi:10.1186/s12887-020-02213-7. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12887-020-02213-7)

[5. (Roy2019Identifying) Jagoree Roy and Martha S. Cyert. Identifying new substrates and functions for an old enzyme: calcineurin. Cold Spring Harbor Perspectives in Biology, 12(3):a035436, July 2019. URL: http://dx.doi.org/10.1101/cshperspect.a035436, doi:10.1101/cshperspect.a035436. This article has 53 citations and is from a peer-reviewed journal.](https://doi.org/10.1101/cshperspect.a035436)

[6. (Pan2022CAMTA1–PPP3CA–NFATc4) Ruijun Pan, Zhou Zhang, Hongtao Jia, Junjun Ma, Chao Wu, Pei Xue, Wei Cai, Xiaoping Zhang, and Jing Sun. Camta1–ppp3ca–nfatc4 multi-protein complex mediates the resistance of colorectal cancer to oxaliplatin. Cell Death Discovery, March 2022. URL: http://dx.doi.org/10.1038/s41420-022-00912-x, doi:10.1038/s41420-022-00912-x. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41420-022-00912-x)

[7. (Chiocco2010Fine) Matthew J. Chiocco, Xuguang Zhu, Donna Walther, Olga Pletnikova, Juan C. Troncoso, George R. Uhl, and Qing-Rong Liu. Fine mapping of calcineurin (ppp3ca) gene reveals novel alternative splicing patterns, association of 5′utr trinucleotide repeat with addiction vulnerability, and differential isoform expression in alzheimer’s disease. Substance Use &amp; Misuse, 45(11):1809–1826, June 2010. URL: http://dx.doi.org/10.3109/10826084.2010.482449, doi:10.3109/10826084.2010.482449. This article has 19 citations.](https://doi.org/10.3109/10826084.2010.482449)

[8. (Rydzanicz2018Novel) Małgorzata Rydzanicz, Małgorzata Wachowska, Erik C. Cook, Paweł Lisowski, Bożena Kuźniewska, Krystyna Szymańska, Sebastian Diecke, Alessandro Prigione, Krzysztof Szczałuba, Aleksandra Szybińska, Agnieszka Koppolu, Victor Murcia Pienkowski, Joanna Kosińska, Małgorzata Wiweger, Grażyna Kostrzewa, Małgorzata Brzozowska, Dorota Domańska-Pakieła, Elżbieta Jurkiewicz, Piotr Stawiński, Agnieszka Gromadka, Piotr Zielenkiewicz, Urszula Demkow, Magdalena Dziembowska, Jacek Kuźnicki, Trevor P. Creamer, and Rafał Płoski. Novel calcineurin a (ppp3ca) variant associated with epilepsy, constitutive enzyme activation and downregulation of protein expression. European Journal of Human Genetics, 27(1):61–69, September 2018. URL: http://dx.doi.org/10.1038/s41431-018-0254-8, doi:10.1038/s41431-018-0254-8. This article has 28 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41431-018-0254-8)

[9. (Wan2014Molecular) Lu Wan, Jisi Ma, Gangyi Xu, Daihua Wang, and Nianlu Wang. Molecular cloning, structural analysis and tissue expression of protein phosphatase 3 catalytic subunit alpha isoform (ppp3ca) gene in tianfu goat muscle. International Journal of Molecular Sciences, 15(2):2346–2358, February 2014. URL: http://dx.doi.org/10.3390/ijms15022346, doi:10.3390/ijms15022346. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms15022346)

[10. (Imai2016Action) Yoichi Imai, Yoshiro Maru, and Junji Tanaka. Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies. Cancer Science, 107(11):1543–1549, November 2016. URL: http://dx.doi.org/10.1111/cas.13062, doi:10.1111/cas.13062. This article has 51 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/cas.13062)

[11. (Myers2017De) Candace T. Myers, Nicholas Stong, Emily I. Mountier, Katherine L. Helbig, Saskia Freytag, Joseph E. Sullivan, Bruria Ben Zeev, Andreea Nissenkorn, Michal Tzadok, Gali Heimer, Deepali N. Shinde, Arezoo Rezazadeh, Brigid M. Regan, Karen L. Oliver, Michelle E. Ernst, Natalie C. Lippa, Maureen S. Mulhern, Zhong Ren, Annapurna Poduri, Danielle M. Andrade, Lynne M. Bird, Melanie Bahlo, Samuel F. Berkovic, Daniel H. Lowenstein, Ingrid E. Scheffer, Lynette G. Sadleir, David B. Goldstein, Heather C. Mefford, and Erin L. Heinzen. De novo mutations in ppp3ca cause severe neurodevelopmental disease with seizures. The American Journal of Human Genetics, 101(4):516–524, October 2017. URL: http://dx.doi.org/10.1016/j.ajhg.2017.08.013, doi:10.1016/j.ajhg.2017.08.013. This article has 45 citations.](https://doi.org/10.1016/j.ajhg.2017.08.013)